Co-Development Agreement & Monetisation Deal

Summary by AI BETAClose X

Arecor Therapeutics has entered a co-development agreement with Sequel Med Tech for AT278, committing up to $1.3 million each to fund development work for a Phase 2 trial, with strategic intent for a broader partnership. Additionally, Arecor has sold royalty rights related to AT220 and milestone and technology access fees related to AT292 to Ligand for up to $11 million (£8.2 million), including a $7 million upfront cash payment and a potential $4 million upon achieving certain commercial milestones, with $1 million expected in 2026. Ligand will also receive warrants for 1,002,739 ordinary shares at an exercise price of 67.39 pence. This agreement extends Arecor's cash runway to the first half of 2027.

Disclaimer*

UK 100

Latest directors dealings